Tag Archive for: anti-GD2

Acquisition

Essential Pharma acquires Renaissance Pharma Ltd

Essential Pharma has acquired Renaissance Pharma Ltd to commercialise  the company’s Phase II program Hu14.18K322A in pedriatric high-risk neuroblastoma.

Read more